Envoy Medical Shareholders approve merger in special meeting held September 28th

Envoy医疗股东批准在9月28日举行的特别会议上合并

Anzu Special Acquisition Corp I announced shareholder approval for the merger September 27th

安祖特别收购公司一世宣布股东批准合并9月27日

Merger anticipated to close September 29th with NASDAQ trading to begin October 2nd under the ticker symbol COCH

合并预计将于9月29日结束，纳斯达克交易将于10月2日开始，以票务符号COCH计算

White Bear Lake, Minnesota--(Newsfile Corp. - September 28, 2023) - Envoy Medical® Corporation ('Envoy'), a hearing health company, today announced that the proposed merger with Anzu Special Acquisition Corp I (NASDAQ: ANZU) (NASDAQ: ANZUU) (NASDAQ: ANZUW) ('Anzu') was approved by a vote of Envoy Medical shareholders in a special meeting held September 28, 2023.

明尼苏达州白熊湖-（新闻档案公司-2023年9月28日）-听证会健康公司EnvoyMedical®Corporation（'Envoy'）今天宣布与安贞特别收购公司I（纳斯达克股票代码：安苏）合并（纳斯达克股票代码：安苏乌）（纳斯达克股票代码：安苏乌）（'Anzu'）于2023年9月28日举行的特别会议上由Envoy Medical股东投票批准。

The vote follows the announcement of approval by Anzu shareholders on September 27, 2023. The business combination was originally signed in April 2023..

投票是在2023年9月27日Anzu股东批准公告之后进行的。该业务组合最初于2023年4月签署。。

'We are excited and humbled by the overwhelming confidence and show of support exhibited by the affirmative Envoy Medical and Anzu shareholder votes,' stated Brent Lucas, Chief Executive Officer of Envoy. 'We continue our steady progress toward disrupting the hearing industry with the first fully implantable cochlear implant.

Envoy首席执行官Brent Lucas说：“我们对肯定特使医疗和Anzu股东投票所展示的压倒性信心和支持表现出的兴奋和沮丧。”我们继续通过第一个完全植入式人工耳蜗在扰乱听力行业方面取得稳步进展。

We know how to build fully implanted hearing devices and we look forward to bringing patients an attractive alternative to other solutions once we have met our clinical and regulatory obligations. We believe that our tremendous team, including a top-notch board of directors and an impressive advisory board of key opinion leaders, positions us well to bring our innovative technology to the market.'.

我们知道如何构建完全植入的听力装置，一旦履行临床和监管义务，我们期待为患者提供其他解决方案的有吸引力的替代方案。我们相信，我们庞大的团队，包括一流的董事会和令人印象深刻的主要意见领袖顾问委员会，使我们能够将创新技术推向市场。

'We believe Envoy Medical has the technology and people to deliver a product that can meaningfully change the lives of the millions of people with profound hearing loss,' said Dr. Whitney Haring-Smith, Envoy board member and co-founding managing partner at Anzu Partners, an investment firm focused on industrial technologies and life sciences.

“我们相信Envoy Medical拥有技术和人员提供一种产品，可以有意义地改变数百万人的生活，造成严重的听力损失，”Whitney Haring Smith博士，Envoy董事会成员和Anzu合作伙伴的共同创始管理伙伴说，一家专注于工业技术和生命科学的投资公司。

'I look forward to working closely with Brent Lucas and the entire team at Envoy Medical to advance their breakthrough hearing health technology.'.

“我期待与Brent Lucas和Envoy Medical的整个团队密切合作，推进他们突破性的听力健康技术。”。

The deal is expected to close September 29, 2023, and begin trading on the NASDAQ Capital Market on October 2, 2023 under the symbol COCH.

该协议预计将于2023年9月29日结束，并于2023年10月2日根据符号COCH在纳斯达克资本市场开始交易。

About Envoy Medical Corporation

关于特使医疗公司

Envoy Medical Corporation, headquartered in White Bear Lake, Minnesota, is a privately held hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Envoy's technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire..

Envoy医疗公司总部设在明尼苏达州白熊湖，是一家私营听力保健公司，致力于在听力损失范围内提供创新医疗技术。Envoy的技术旨在改变听力行业的范式，并为提供者和患者带来他们想要的听力装置。。

Envoy is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and ultimately quality of life.

Envoy致力于推动超越现状的听力技术，为患者提供更好的获取，可用性，独立性和最终的生活质量。

About the Fully Implanted Acclaim® Cochlear Implant

关于完全植入的Acclaim®人工耳蜗

We believe the fully implanted Acclaim® Cochlear Implant is a first-of-its-kind cochlear implant. Envoy's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

我们相信完全植入的Acclaim®人工耳蜗是首创的人工耳蜗。Envoy的完全植入技术包括一个传感器，旨在利用耳朵的自然解剖结构而不是麦克风来捕捉声音。

The Acclaim is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim will only be indicated for adults who have been deemed adequate candidates by a qualified physician.

广受好评的目的是解决助听器无法充分解决的严重至严重的感音神经性听力损失。只有合格的医生认为足够的候选人的成年人才能获得好评。

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. We believe the Acclaim was the first hearing-focused device to receive Breakthrough Device Designation and may still be the only hearing focused medical technology to receive the designation..

广受好评的人工耳蜗于2019年获得美国食品和药物管理局（FDA）的突破性设备名称。我们相信，好评是第一个获得突破性设备指定的听力聚焦设备，可能仍然是唯一获得指定的听力聚焦医疗技术。。

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by United States law to investigational use.

小心完全植入的Acclaim人工耳蜗是一种研究设备。受美国法律限制用于研究用途。

Important safety information for the Esteem can be found at: https://www.envoymedical.com/safety-information.

有关尊重的重要安全信息，请参阅：https://www.envoymedical.com/safety-information.

About Anzu Special Acquisition Corp I

关于安祖特别收购公司I

Anzu is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.

Anzu是为实现合并，股权交换，资产收购，股权购买，重组或类似业务组合而成立的专项收购公司。

Forward-Looking Statements

前瞻性声明

This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'will,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'target' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking.

本新闻稿包括1995年“美国私人证券诉讼改革法”的“安全港”规定含义内的“前瞻性声明”。前瞻性陈述可以通过使用诸如“估计”，“计划”，“项目”，“预测”，“意图”，“将会”，“期望”，“预期”，“相信”，“寻求”，“目标”或其他类似的表达式来预测或指示未来的事件或趋势，或者不是历史事项的陈述，但缺少这些词语并不意味着陈述不是前瞻性的。

Such statements may include, but are not limited to, statements regarding the expectations of Envoy or Anzu concerning the outlook for their business, technologies, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets, as well as any information concerning possible or assumed future operations of Envoy.

这些声明可能包括但不限于关于难民或安贞对其业务，技术，生产力，未来运营改进和资本投资的计划和目标，运营绩效，未来市场状况或经济绩效的期望的声明。资本和信贷市场的发展，以及关于难民可能或假定未来行动的任何信息。

Forward-looking statements also include statements regarding the expected benefits of the Proposed Business Combination. The forward-looking statements contained in this press release reflect Envoy's and Anzu's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement.

前瞻性声明还包括关于拟议业务组合预期收益的声明。本新闻稿中所载的前瞻性声明反映了难民和安贞目前对未来事件的看法，并面临许多已知和未知的风险，不确定性，假设和情况变化，可能导致其实际结果与任何前瞻性声明。

Neither Envoy nor Anzu guarantees that the transactions and events described will happen as described (or that they will happen at all). In particular, there can be no assurance that the Proposed Business Combination will close on the expected timeline or at all. These forward-looking .

Envoy和Anzu都不保证所描述的交易和事件将如所述发生（或者它们将完全发生）。特别是，不能保证拟议的业务组合将在预期的时间表或根本关闭。这些前瞻性。

Additional Information and Where to Find It

其他信息以及在哪里找到它

In connection with the Proposed Business Combination, Anzu has filed the Registration Statement with the SEC. The Registration Statement includes a proxy statement in connection with Anzu's solicitation of proxies for the vote by Anzu's stockholders with respect to the Proposed Business Combination and other matters as may be described in the Registration Statement, as well as a prospectus relating to the offer and sale of the securities to be issued in connection with the Proposed Business Combination.

关于拟议的商业组合，Anzu已向SEC提交了注册声明。注册声明包括一份代理声明，涉及Anzu就拟议的商业组合和其他事项征求Anzu股东投票的代理人。可能在注册声明中描述，以及与拟议的商业组合有关的要发行证券的报价和销售的IPO。

On September 14, 2023, Anzu commenced the mailing of the definitive proxy statement/prospectus to its stockholders as of September 5, 2023, the record date established for voting on the Proposed Business Combination and other matters described in the Registration Statement. Anzu also plans to file other relevant documents with the SEC regarding the Proposed Business Combination.

截至2023年9月5日，Anzu于2023年9月5日开始将明确的代理声明/IPO邮寄给其股东，该记录日期是为对拟议的业务组合和注册声明中描述的其他事项进行投票而确定的。Anzu还计划向SEC提交有关拟议业务组合的其他相关文件。

This press release is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Anzu will send to its stockholders in connection with the Proposed Business Combination. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, THIS PRESS RELEASE AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION..

本新闻稿不能替代注册声明，最终代理声明/IPO或Anzu将与拟议的业务组合相关联的任何其他文件。敦促投资者和担保人阅读代理声明/承销说明书，本新闻稿和向证券交易委员会提交的其他相关文件，因为它们将包含重要信息。。

Copies of the Registration Statement, the definitive proxy statement/prospectus and other documents filed by Anzu or Envoy with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

注册声明的副本，Anzu或Envoy向SEC提交的最终代理声明/IPO和其他文件可在SEC的网站www.SEC.gov免费获取。

Participants in the Solicitation

参与征集

Anzu, Envoy and their respective directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Anzu's stockholders in connection with the Proposed Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Anzu's stockholders in connection with the Proposed Business Combination and a description of their direct and indirect interests are contained in the Registration Statement.

根据SEC规则，Anzu，Envoy及其各自的董事，执行官，管理层和员工的其他成员可能被视为参与Anzu股东代理与拟议业务组合的请求。有关根据SEC规则可能被视为参与Anzu股东征集的与拟议业务组合有关的人员的信息以及对其直接和间接利益的描述均包含在注册声明中。

Information regarding Anzu's directors and executive officers can be found in its Annual Report on Form 10-K filed with the SEC on April 3, 2023. These documents can be obtained free of charge at the SEC's website at www.sec.gov..

有关Anzu董事和执行官的信息可以在2023年4月3日提交给SEC的表格10-K的年度报告中找到。这些文件可以在SEC的网站www.SEC.gov上免费获得。。

No Offer or Solicitation

没有报价或征求

This press release relates to the Proposed Business Combination and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Proposed Business Combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law.

本新闻稿涉及拟议的商业组合，既不是购买报价，也不是根据拟议的商业组合或其他方式征求出售，订阅或购买任何证券或在任何辖区征集任何投票的报价。，也不应进行任何销售，违反适用法律的任何管辖范围内的发行，转让或证券。

No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, or an exemption therefrom, and otherwise in accordance with applicable law..

除根据1933年证券法第10条的要求或免除证券外，以及根据适用法律，不得以任何方式向证券报价。。

###

###

Investor Contact:

投资者联系：

Matt Kreps

马特·克雷普斯

Darrow Associates Investor Relations

达罗联合投资者关系

(214) 597-8200

(214) 597-8200

mkreps@darrowir.com

mkreps@darrowir.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/182224

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/182224